21:27 , Jun 16, 2017 |  BC Week In Review  |  Clinical News

MD Anderson starts Phase I of evofosfamide plus Yervoy in solid tumors

Threshold Pharmaceuticals Inc. (NASDAQ:THLD) said the University of Texas MD Anderson Cancer Center (Houston, Texas) started a Phase I trial to evaluate evofosfamide plus Yervoy ipilimumab in up to 69 patients with metastatic or locally...
20:07 , Mar 24, 2017 |  BC Week In Review  |  Company News

Molecular Templates, Threshold deal

Molecular Templates is reverse-merging with Threshold. The combined entity would keep Molecular Templates' name, and intends to change its NASDAQ ticker to MTEM. Existing Molecular Templates shareholders will own 66% of the combined company, while...
23:04 , Mar 17, 2017 |  BC Extra  |  Company News

Molecular Templates finds public path via Threshold

Molecular Templates Inc. (Austin, Texas) is reverse-merging with Threshold Pharmaceuticals Inc. (NASDAQ:THLD). The combined entity would keep Molecular Templates' name, and intends to change its NASDAQ ticker to MTEM. Existing Molecular Templates shareholders will own...
18:32 , Nov 18, 2016 |  BC Week In Review  |  Clinical News

Tarloxotinib: Development discontinued

Threshold discontinued development of tarloxotinib after reporting interim data from the Phase II TH-CR-601 and TH-CR-602 trials of the compound to treat NSCLC and squamous cell carcinoma of the head and neck (SCCHN) or skin...
18:26 , Nov 18, 2016 |  BC Week In Review  |  Clinical News

Tarloxotinib: Development discontinued

Threshold discontinued development of tarloxotinib after reporting interim data from the Phase II TH-CR-601 and TH-CR-602 trials of the compound to treat non-small cell lung cancer (NSCLC) and squamous cell carcinoma of the head and...
07:00 , Oct 31, 2016 |  BC Week In Review  |  Company News

Caris Life Sciences, Threshold deal

Caris and Threshold partnered to develop a companion diagnostic for Threshold’s evofosfamide using Caris’ ADAPT biotargeting system. Evofosfamide is a hypoxia-activated cytotoxic 2-nitroimidazole prodrug of the DNA alkylator bromoisophosphoramide mustard (Br-IPM). Late last year, the...
08:00 , Jan 4, 2016 |  BioCentury  |  Finance

Big band swing

Many investors treated biotech's dismal 3Q15 as a buying opportunity, and the effects were apparent in 4Q15. All of the market cap bands showed positive gains save for the microcaps. Big biotechs led the charge...
08:00 , Jan 4, 2016 |  BC Week In Review  |  Company News

Threshold cancer news

Threshold will reduce headcount by about 66% to 20-25 to focus resources on two ongoing Phase II trials of tarloxotinib ( TH-4000 ) to treat non-small cell lung cancer (NSCLC) and squamous cell carcinomas of...
08:00 , Dec 14, 2015 |  BC Week In Review  |  Clinical News

Evofosfamide: Development discontinued

Threshold and partner Merck discontinued development of evofosfamide to treat pancreatic cancer after the double-blind, international Phase III MAESTRO trial in 693 patients with previously untreated, locally advanced, unresectable or metastatic pancreatic adenocarcinoma showed that...
08:00 , Dec 14, 2015 |  BC Week In Review  |  Clinical News

Evofosfamide: Development discontinued

Threshold and partner Merck discontinued development of evofosfamide to treat STS after the open-label, international Phase III TH-CR-406/SARC021 trial in 640 patients with locally advanced unresectable or metastatic STS previously untreated with chemotherapy showed that...